A UK study published Oct. 30, 2026, in the British Journal of Dermatology compared 320,220 people with psoriasis with 1,706,424 matched people and found links with conditions across the body, including liver disease, substance misuse and interstitial lung disease.
A meta-analysis published Oct. 16, 2026, in BioDrugs found that 2.17% of people treated with biologics for psoriasis developed eczema-like reactions, most often with IL-17 inhibitors and least with IL-23 inhibitors.
A large records study published in October 2026 in Experimental Dermatology found that people with eczema treated with dupilumab didn't have a higher two-year risk of psoriasis than those on steroid creams, other biologics or JAK inhibitors.